Literature DB >> 2756190

Computed tomography and magnetic resonance imaging of the pericardium.

M C Olson1, H V Posniak, V McDonald, R Wisniewski, R Moncada.   

Abstract

Computed tomography is an established modality for the evaluation of the pericardium. It is used to evaluate complicated pericardial effusions, pericardial thickening, calcific pericarditis, pericardial cysts, postoperative changes and primary and metastatic neoplasms of the pericardium. Magnetic resonance imaging is being used with increasing frequency in the evaluation of pericardial disease. It offers advantages over computed tomography, including a potential for tissue characterization, absence of ionizing radiation or need for intravenous contrast medium, and the ability to scan in any plane. Disadvantages include greater cost, longer examination times and the inability to identify calcification positively.

Entities:  

Mesh:

Year:  1989        PMID: 2756190     DOI: 10.1148/radiographics.9.4.2756190

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  3 in total

Review 1.  The utility of cardiovascular magnetic resonance in constrictive pericardial disease.

Authors:  Vignendra Ariyarajah; Davinder S Jassal; Iain Kirkpatrick; Raymond Y Kwong
Journal:  Cardiol Rev       Date:  2009 Mar-Apr       Impact factor: 2.644

2.  Effectiveness of computed tomography attenuation values in characterization of pericardial effusion.

Authors:  Mehmet Serkan Çetin; Elif Hande Özcan Çetin; Mustafa Özdemir; Serkan Topaloğlu; Dursun Aras; Ahmet Temizhan; Sinan Aydoğdu
Journal:  Anatol J Cardiol       Date:  2017-01-17       Impact factor: 1.596

Review 3.  Quantitative magnetic resonance imaging of pulmonary hypertension: a practical approach to the current state of the art.

Authors:  Andrew J Swift; Jim M Wild; Scott K Nagle; Alejandro Roldán-Alzate; Christopher J François; Sean Fain; Kevin Johnson; Dave Capener; Edwin J R van Beek; David G Kiely; Kang Wang; Mark L Schiebler
Journal:  J Thorac Imaging       Date:  2014-03       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.